Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Personalis, Inc. (NASDAQ:PSNL) have received an average rating of “Moderate Buy” from the seven research firms that are currently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $11.00.

A number of brokerages recently weighed in on PSNL. Guggenheim lifted their price objective on shares of Personalis from $12.00 to $13.00 and gave the company a “buy” rating in a report on Monday, January 26th. BTIG Research decreased their price objective on shares of Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Needham & Company LLC raised their target price on Personalis from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, February 27th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Finally, Wall Street Zen cut Personalis from a “hold” rating to a “sell” rating in a report on Saturday, May 9th.

Personalis Stock Performance

Shares of NASDAQ:PSNL opened at $8.47 on Monday. The company has a market cap of $886.98 million, a price-to-earnings ratio of -8.30 and a beta of 1.96. Personalis has a 12 month low of $3.84 and a 12 month high of $11.50. The company has a 50-day moving average price of $6.56 and a 200 day moving average price of $8.02.

Personalis (NASDAQ:PSNL) last announced its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The company had revenue of $15.47 million during the quarter, compared to analysts’ expectations of $14.49 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, equities analysts forecast that Personalis will post -1.06 EPS for the current year.

Hedge Funds Weigh In On Personalis

Hedge funds have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd lifted its stake in shares of Personalis by 76.1% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after buying an additional 1,479 shares in the last quarter. Deutsche Bank AG lifted its holdings in Personalis by 4.5% in the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after acquiring an additional 1,655 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after purchasing an additional 2,395 shares during the period. Howland Capital Management LLC boosted its stake in Personalis by 0.9% during the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock worth $1,872,000 after buying an additional 2,500 shares during the period. Finally, Intech Investment Management LLC boosted its position in shares of Personalis by 23.4% during the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock worth $162,000 after purchasing an additional 3,851 shares during the period. Hedge funds and other institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.